Optimizing topical therapies for treating psoriasis: a consensus conference.
In 2010, an expert committee of physicians and researchers in the field of dermatology working together as the Psoriasis Process of Care Consensus Panel developed consensus guidelines for the treatment of psoriasis. As much as possible, the guidelines were evidence based but also included the extensive clinical experience of the dermatologists. Psoriasis is a lifelong disease that requires long-term treatment and 80% of psoriasis patients have mild to moderate disease. Topical therapies play an important role in the treatment of psoriasis, especially in patients with mild to moderate disease. Patients usually start with monotherapy; however, in more severe cases (> 10% body surface area [BSA], severely impaired quality of life [QOL], or recalcitrant psoriatic lesions), multiple treatment modalities may be used as part of combination, sequential, or rotational therapeutic regimens. Main treatment options include topical steroids, systemic therapies, topical vitamin D treatments such as vitamin D3 ointment, retinoids, phototherapy, and biologic therapies. Other topical therapies include the following steroid-sparing agents: coal tar, anthralin, calcineurin inhibitors, keratolytics, and emollients. Therapeutic considerations also should focus on adherence, improving QOL, and promoting a good patient-physician relationship.
Mount Sinai Medical Center, New York, New York, USA.
Joshua A
JA
Zeichner
Mark G
MG
Lebwohl
Alan
A
Menter
Jerry
J
Bagel
James Q
JQ
Del Rosso
Boni E
BE
Elewski
Steven R
SR
Feldman
Leon H
LH
Kircik
John
J
Koo
Linda Stein
LS
Gold
Emil
E
Tanghetti
D000279:Administration, Cutaneous; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003880:Dermatology / Q000379:methods; D006801:Humans; D010353:Patient Education as Topic / Q000379:methods; D011565:Psoriasis / Q000188:drug therapy* / Q000503:physiopathology; D012720:Severity of Illness Index
D003879:Dermatologic Agents